JMI Laboratories, North Liberty, IA 52317, USA.
JMI Laboratories, North Liberty, IA 52317, USA.
J Glob Antimicrob Resist. 2020 Mar;20:118-123. doi: 10.1016/j.jgar.2019.07.007. Epub 2019 Jul 17.
The in vitro antimicrobial activities of telavancin and comparator antimicrobials were evaluated against recent Staphylococcus aureus (S. aureus) clinical isolates collected in the United States of America (USA).
A total of 15882 S. aureus isolates were collected (2014-2016) as part of the SENTRY Antimicrobial Surveillance Program from sites located in all US Census Bureau divisions. Broth microdilution MIC values were measured using current reference methods. Data were stratified by year and census division, and resistance rates were analysed for significant trends. Previously published data on methicillin-resistant S. aureus (MRSA) and multidrug-resistant (MDR) MRSA isolates (collected 2011-2013) were merged with the current isolate set to examine longer term resistance trends.
Telavancin antimicrobial activity against MRSA and MDR MRSA isolates (MIC values, 0.03/0.06μg/mL for both subsets) remained unchanged over the 3-year surveillance period, and all isolates were susceptible to telavancin. No difference in telavancin activity was noted when MIC data were stratified by year or US Census Bureau division. When merged data (2011-2016) were analysed, the MRSA rate decreased for the entire USA and six individual census divisions, although the overall rate remained considerable. The overall US MDR MRSA rate also remained considerable and was unchanged from 2011-2016.
The sustained potent activity of telavancin against US S. aureus isolates (100% susceptible) and the high rates of MRSA and MDR MRSA in the USA support the continued use of telavancin to treat indicated serious infections caused by S. aureus.
评估替拉凡星与对照抗菌药物对近期分离自美国的金黄色葡萄球菌（S. aureus）临床分离株的体外抗菌活性。
共收集了 15882 株金黄色葡萄球菌分离株（2014-2016 年），作为 SENTRY 抗菌监测计划的一部分，来自美国所有人口普查局分区的监测点。使用当前的参考方法测量肉汤微量稀释 MIC 值。根据年份和人口普查局分区对数据进行分层，并对耐药率进行分析以确定显著趋势。将先前发表的关于耐甲氧西林金黄色葡萄球菌（MRSA）和多药耐药（MDR）MRSA 分离株的数据（2011-2013 年收集）与当前分离株集合并用于研究长期耐药趋势。
替拉凡星对 MRSA 和 MDR MRSA 分离株（MIC 值，两亚组均为 0.03/0.06μg/mL）的抗菌活性在 3 年监测期间保持不变，所有分离株均对替拉凡星敏感。当 MIC 数据按年份或美国人口普查局分区分层时，替拉凡星的活性没有差异。当分析合并数据（2011-2016 年）时，整个美国和六个个别人口普查局分区的 MRSA 率下降，尽管总体率仍然相当高。美国整体 MDR MRSA 率仍然相当高，且 2011-2016 年没有变化。
替拉凡星对美国金黄色葡萄球菌分离株（100%敏感）持续具有强大的活性，以及美国 MRSA 和 MDR MRSA 的高发生率支持继续使用替拉凡星治疗由金黄色葡萄球菌引起的有指征的严重感染。
